Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

This is also an important milestone in our product strategy for our expansion into the larger Latin American market

Caplin Point Laboratories’ subsidiary acquires land in Mexico

The investment in land is Rs. 19.85 crore

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025

Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr

Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru

Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr

EPS climbs to Rs 9.25 for the quarter

Caplin Steriles receives USFDA approval for Calcium Gluconate Injection

Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million

Caplin Steriles gets USFDA approval for potassium phosphates injection

Caplin Steriles gets FDA approval for desmopressin

Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease

Caplin Steriles gets USFDA approval for Sodium Phosphate injection

Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake